Selina Yeasmin
Adult Health · Baltimore, MDNPI 1558607077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,876 of the $7,776 with a category attached, or 88.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,641 and has fallen 77.0% since, to $609 in 2025. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$722
- Lilly USA, LLC$698
- Biogen$687
- Amgen$686
- Novartis$619
- Teva Pharmaceuticals USA, Inc.$496
- plus $4K from 19 others
What the payments were for
- Consulting fees$4756%
- Speaking & faculty fees$3505%
- Food & beverage$6,87688%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $722 |
| Lilly USA, LLC | 37 | $698 |
| Biogen | 20 | $687 |
| Amgen | 27 | $686 |
| Novartis | 35 | $619 |
| Teva Pharmaceuticals USA, Inc. | 17 | $496 |
| EMD Serono, Inc. | 21 | $493 |
| Bristol Myers Squibb | 33 | $454 |
| Lundbeck LLC | 26 | $424 |
| AstraZeneca(2 entities) | 6 | $407 |
| Biohaven Pharmaceuticals, Inc. | 9 | $379 |
| Genentech USA, Inc. | 13 | $305 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $250 |
| Sanofi | 3 | $244 |
| Banner Life Sciences, LLC | 10 | $205 |
| Amneal Pharmaceuticals LLC | 11 | $193 |
| Pfizer | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| TG Therapeutics, Inc. | 3 | $65 |
| Kyowa Kirin, Inc. | 3 | $56 |
| Impel Pharmaceuticals Inc. | 3 | $49 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| UCB, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,776 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 37 | $331,956 |
| Dimethyl Fumarate | 76 | $220,488 |
| VumerityDiroximel Fumarate | 24 | $212,625 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 27 | $211,545 |
| Kesimpta PenOfatumumab | 22 | $193,463 |
| TecfideraDimethyl Fumarate | 19 | $173,704 |
| Nurtec OdtRimegepant Sulfate | 56 | $109,984 |
| TysabriNatalizumab | 12 | $97,906 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $96,710 |
| Glatiramer Acetate | 22 | $74,737 |
| Aimovig AutoinjectorErenumab-Aooe | 69 | $59,183 |
| Emgality PenGalcanezumab-Gnlm | 67 | $57,672 |
| UbrelvyUbrogepant | 39 | $54,441 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 25 | $21,801 |
| Dalfampridine ErDalfampridine | 27 | $11,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera, Tysabri, Avonex (4 Pack) | $687 | $580,94567 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $496 | $331,95637 claims |
| PfizerNurtec Odt | $136 | $109,98456 claims |
| AbbVieUbrelvy | $722 | $54,44139 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $193 | $4,81015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.
Other adult health in Baltimore
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Monica LovinsBaltimore$18K
- Elizabeth ChandlerBaltimore$17K
- Clifton DawsonBaltimore$14K
- Andrea ArroyoBaltimore$8K
- Kathleen CostelloBaltimore$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.